solid-phase synthesis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
However, he can't open the hatch by himself. The player must fight through the asylum and the local theater, which is now overrun with zombified soldiers, to meet him on the other side. The player and the deputy take off in a police helicopter. The game reaches its climax as the player and the deputy are forced to fight Dr. Franklin, who, after taking the full impact of the blast in episode 2, has been rebuilt into a half-zombie, half-machine cyborg. After the doctor's defeat, the player is pursued by Sheriff Rockwood in another helicopter with a mounted mini-gun. The player must defeat the sheriff and send him plummeting toward one of the great lakes before exploding. The game ends with the player and the deputy flying off into the sunrise while the game plays "You Are What I Eat" along with the end credits.
Drug prescriptions are very commonly written to be regimented to patients along with any therapy they receive. There are three major pillars of psychotherapy that treatment strategies are most regularly drawn from. Humanistic psychology attempts to put the "whole" of the patient in perspective; it also focuses on self exploration. Behaviorism is a therapeutic school of thought that elects to focus solely on real and observable events, rather than mining the unconscious or subconscious. Psychoanalysis, on the other hand, concentrates its dealings on early childhood, irrational drives, the unconscious, and conflict between conscious and unconscious streams. In recent years, mindfulness practices involving present-moment awareness have gained popularity and have been shown to be effective in psychiatric treatment.
Lambert (2026) reevaluates the affinites of "Platybelodon" barnumbrowni from the Late Miocene of Nebraska (United States), transferring the species to the genus Protanancus (the first record of the genus from North America), as well as describing "Serbelodon" burnhami and an unnamed taxon from the Bone Valley of Florida as sharing affinities with Protanancus. Armaroli et al. (2026) reconstruct the ecology and habitat use of straight-tusked elephants from the Neumark-Nord site (Germany) on the basis of the study of the strontium isotopic composition of their remains and on the basis of proteomic analysis, reporting evidence indicating that the studied elephant assemblage included both male and female individuals from geographically separated populations that migrated to the lake basins of Neumark-Nord, and evidence of seasonal mobility of the studied individuals, including probable evidence of two male individuals dwelling in mountainous areas within 300 km of Neumark-Nord. Farrell et al. (2026) identify fossil material of a straight-tusked elephant from the mid-Pleistocene North Bridge Acheulian site north of Gesher Benot Ya'aqov (Israel), and interpret its tooth wear and isotopic composition of its tooth enamel, coupled with the studies of local palynological assemblages and climatic reconstructions, as indicative of a mixed-feeding strategy of the studied individual, as well as indicating that it lived in a mosaic woodland-wetland habitat with a Mediterranean climate. Kusaka et al.
Oenococcus oeni, the LAB species most often desired by winemakers to carry out malolactic fermentation, can be found in the vineyard, but often at very low levels. While moldy, damaged fruit has the potential to carry a diverse flora of microbes, the LAB most often found on clean, healthy grapes after harvest are species from the Lactobacillus and Pediococcus genera. After crushing, microbiologists usually find populations under 103 colony forming units/mL containing a mix of P. damnosus, L. casei, L. hilgardii, and L. plantarum, as well as O. oeni. For musts that do not receive an early dose of sulfur dioxide to "knock back" these wild populations of LAB, this flora of bacteria compete with each other (and the wine yeasts) for nutrients early in fermentation. In the winery, multiple contact points can be home to native population of LAB including oak barrels, pumps, hoses, and bottling lines. For wines where malolactic fermentation is undesirable (such as fruity white wines), the lack of proper sanitation of wine equipment can lead to the development of unwanted MLF and result in wine faults. In cases of oak barrels where full and complete sanitation is almost impossible, wineries often mark barrels that have contained wines going through MLF and keep them isolated from "clean" or brand new barrels that they can use for wines that are not destined to go through MLF.
== History == In 2003, Lifeline Therapeutics, a privately held Denver-based nutraceutical licensing and marketing company, entered into an agreement with Massachusetts biotechnology company CereMedix for the rights to market CMX-1152, an experimental peptide-based compound, under the brand name "Protandim" (also sometimes referred to at that time as "Rholen," "Rejuven8r" and "ependymin"). CereMedix was a ten percent owner of Lifeline and members of the CereMedix management board served on Lifeline's board of directors. CMX-1152 was claimed to upregulate the production of the endogenous antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase, and to offset the aging process. CMX-1152 was due to be marketed as an over the counter anti-aging pill in June 2004 after completing human clinical trials. However, plans to market the CMX-1152 version of Protandim fell through and in April 2004 Lifeline Therapeutics announced that it would instead be marketing a different (non-peptide) dietary supplement under the name "Protandim CF" (to distinguish it from the peptide version initially developed by Cermedix). The new version of Protandim, a combination of five common herbal ingredients including turmeric and green tea was invented following "months of extensive research and development" by Lifeline employees Paul Myhill and William Driscoll (a former oil company executive), who together hold the patent on the product, and it was launched in February 2005. Myhill and Driscoll resigned from the company later that year.
Sources: en.wikipedia.org
== Essays == "The Philosophy of Dress" First published in The New-York Tribune (1885), published for the first time in book form in Oscar Wilde On Dress (2013). "The Decay of Lying" First published in Nineteenth Century (1889), republished in Intentions (1891). "Pen, Pencil and Poison" First published in the Fortnightly Review (1889), republished in Intentions (1891). "The Soul of Man under Socialism" First published in the Fortnightly Review (1891), republished in The Soul of Man (1895), privately printed. ("The Soul of Man Under Socialism" on Wikisource) Intentions (1891) Wilde revised his dialogues on aesthetic subjects for publication in this volume, which comprises: "The Critic as Artist" "The Decay of Lying" "The Truth of Masks" "Phrases and Philosophies for the Use of the Young" first published in the Oxford student magazine The Chameleon, December 1894) ("Phrases and Philosophies for the Use of the Young" on Wikisource) "A Few Maxims For The Instruction Of The Over-Educated" First published, anonymously, in the 1894 November 17 issue of Saturday Review.
Compounds of vitamin B6 contain a pyridine ring. The actual active compound is pyridoxal phosphate. However, pyridoxal as well as pyridoxine, pyridoxamine, and their phosphates can readily be converted into pyridoxal phosphate. Consequently, all six compounds are assigned to the vitamin B6 group. In humans, pyridoxal phosphate acts as a cofactor in a very large number of biological processes, including approximately 140 known enzymatic reactions. About 4% of all cellular enzymes require pyridoxal phosphate as a cofactor. Vitamin B6 must be obtained from the diet and is found in substantial amounts in both animal and plant foods. Animal sources include fish, liver, and other offal. Plant sources include potatoes, nuts, avocados, and bananas. In plant foods, the vitamin B6 precursor pyridoxine-5'-glucoside predominates. The principal function of pyridoxal phosphate in these reactions is the stabilization of negative charges in amino compounds. Such reactions include transaminations, decarboxylations, as well as various substitution reactions and elimination reactions. Nicotinamide adenine dinucleotide (NAD) is likewise a cofactor and is essential for many redox reactions in biological systems. These include the degradation of glucose to pyruvic acid during glycolysis. NAD is also required for the citrate cycle. In addition, it acts as a regulator of transcription factors, for example in the circadian rhythm.
=== Types of surgical incision === To realise the emplacement of a prosthetic breast (saline-solution or silicone-gel) into the implant-pocket of the woman patient, plastic surgeons employ five types of surgical incision:
== Epidemiology == The HbS gene can be found in every ethnic group. The highest frequency of sickle cell disease is found in tropical regions, particularly sub-Saharan Africa, tribal regions of India, and the Middle East. About 80% of sickle cell disease cases are believed to occur in Sub-Saharan Africa. Migration of substantial populations from these high-prevalence areas to low-prevalence countries in Europe has dramatically increased in recent decades and in some European countries, sickle cell disease has now overtaken more familiar genetic conditions such as haemophilia and cystic fibrosis. In 2015, it resulted in about 114,800 deaths. Sickle cell disease occurs more commonly among people whose ancestors lived in tropical and subtropical sub-Saharan regions where malaria is or was common. Where malaria is common, carrying a single sickle cell allele (trait) confers a heterozygote advantage; humans with one of the two alleles of sickle cell disease show less severe symptoms when infected with malaria. This condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. The parents each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.